PharmAthene announces successful non-clinical animal study of anthrax vaccine

PharmAthene, Inc., announced on Friday a non-clinical animal data study of its SparVax next-generation anthrax vaccine program showed the vaccine to be effective against anthrax.

Director of Immunology at PharmaAthene Dr. Sherry Crowe presented the results of the study at the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy in Denver, Colo. The presentation was titled "Recombinant Protective Antigen Vaccine (SparVax) Provides Protection against Lethal Challenge with Bacillus anthracis in New Zealand White Rabbits."

The study's researchers gave New Zealand White rabbits increasing doses of SparVax, which ranged from 0.003 micrograms to 1.0 micrograms of rPA. Control animals received no vaccine or saline. Following this, the rabbits were exposed to B. anthracis spores.

The vaccine proved to be effectively protect the immunized rabbits from lethal inhalation of anthrax with no adverse consequences observed. Researchers noted a stimulated dose-dependent antibody response from the vaccine, which showed a correlation to survival.

"PharmAthene is pleased to be working in partnership with the Biomedical Advanced Research and Development Authority towards our mutual goal of advancing novel, next-generation anthrax vaccines to address important national security initiatives," PharmAthene President and CEO Eric I. Richman said. "We look forward to continuing this progress and commencing a Phase 2 clinical trial of SparVaxlater this year."